Michiel De Maaker

Michiel de Maaker

Technician

+31 20 512 2034 m.d.maaker@nki.nl Marleen Kok Hugo Horlings

In March 2017 I started as technician to work on the TONIC trial. This study investigates the effect and effectiveness of treatment with the new drug nivolumab (immunotherapy). The new drug is administered after a low dose of radiation or chemotherapy. I also continued my work with the Young Boost Trial.

The main objective of theYoung Boost trial is to compare the effect of a high boost dose (26 Gy) with a low boost dose (16 Gy) in breast conserving therapy, on the local recurrence rate.

Additional objectives are:

To test the genotypic and phenotypic profiles of breast tumors in young patients with invasive breast cancer, and its relation  to:

a. Local recurrence after breast conserving treatment
b. Lymph node metastases
c. Distant metastases and survival
d. Radio sensitivity
e. Age


This site uses cookies

This website uses cookies to ensure you get the best experience on our website.